• How Is Your Day?
  • Why is access to all brands of plasma protein therapies important?

Why is access to all brands of plasma protein therapies important?

Pobierz w formacie PDF
One-size-fits-all policies are unsuitable for plasma protein therapies and endanger patient health. Each therapy is unique due to the pharmacologic and manufacturing differences that exist across different brands and patients’ unique responses to the treatments. Plasma protein therapies are non-interchangeable, sole-source biologics, therefore it is essential that patients have access to their medically justifiable therapy.

10-year survival rate of patients with COMMON VARIABLE IMMUNE DEFICIENCY, by year

  • 37%: 1971
  • 78%: 1993
  • 90%: 2008
Source: Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008; 112(2):277–286.

Life expectancy of a patient born with HEMOPHILIA, by year

  • 1900: 13 years
  • 1960: 20 years
  • 2017: 77 years
Source: Aledort, L. The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline. Haemophilia. 2016; 22(2):676–683.
american_academy_of_neurology

„Biorąc pod uwagę zróżnicowanie tych chorób, bardzo ważne jest zindywidualizowane leczenie, uzależnione od potrzeb pacjenta i oceny lekarza."

American Academy of Neurology
Alpha_1_Foundation

„Ograniczanie dostępności leczenia suplementacyjnego w jakikolwiek sposób, zwłaszcza do jednego produktu, jest niedopuszczalne."

Alpha-1 Foundation
haea

„Ponieważ nie wszyscy pacjenci reagują tak samo na te same leki, obowiązkiem koordynującego lekarza jest praca z każdym pacjentem, by określić optymalne leczenie dla danego pacjenta."

haea

Value to the system The economic impact of diagnosing a Primary Immunodeficiency Disease and treating an individual with immunoglobulin therapy represents an average savings of $55,882 per year.

Source: Modell, V., Quinn, J., Ginsberg, G., Gladue, R., Orange, J., & Modell, F. (2017). Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement. Immunologic Research.

The rare and chronic diseases treated by plasma protein therapies are often difficult to diagnose, treat, and manage. Accordingly, to ensure the best possible health outcomes for patients, the individuals who rely on plasma protein therapies as part of their lifesaving treatment require medically appropriate access to the specialists who best understand the complexities of their diseases. A relatively select few specialists across the country have developed the enhanced knowledge and experience necessary to effectively treat the rare diseases treated by plasma protein therapies. Therefore, we recommend payer policies that allow individuals with plasma protein deficiencies access to those physicians who have experience treating these rare conditions.

Immune Deficiency Foundation. (2009).